Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
$1.51
+2.0%
$1.65
$1.35
$5.92
$3.96M1.888,639 shs17,052 shs
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
$0.63
+1.6%
$0.76
$0.47
$13.98
$1.68M0.8546,434 shs14,349 shs
Femasys Inc. stock logo
FEMY
Femasys
$1.33
+4.7%
$1.60
$0.25
$4.75
$29.39M-3638,415 shs280,799 shs
Neovasc Inc. stock logo
NVCN
Neovasc
$30.03
$29.69
$4.59
$30.07
$82.28M1.756,993 shs1 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
+5.73%+5.00%-11.58%-24.03%-71.37%
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
+0.81%+9.65%-22.15%-25.60%-90.15%
Femasys Inc. stock logo
FEMY
Femasys
+4.72%+1.53%-19.88%+68.35%+53.05%
Neovasc Inc. stock logo
NVCN
Neovasc
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
1.3028 of 5 stars
3.53.00.00.01.10.00.6
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Femasys Inc. stock logo
FEMY
Femasys
2.5372 of 5 stars
3.52.00.00.03.22.50.6
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
3.00
Buy$10.00561.42% Upside
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
2.00
HoldN/AN/A
Femasys Inc. stock logo
FEMY
Femasys
3.00
Buy$11.33752.13% Upside
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/A

Current Analyst Ratings

Latest AEMD, BJDX, FEMY, and NVCN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2024
Femasys Inc. stock logo
FEMY
Femasys
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00
4/1/2024
Femasys Inc. stock logo
FEMY
Femasys
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $12.00
3/21/2024
Femasys Inc. stock logo
FEMY
Femasys
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00
3/21/2024
Femasys Inc. stock logo
FEMY
Femasys
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
3/20/2024
Femasys Inc. stock logo
FEMY
Femasys
Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $10.00
3/4/2024
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$23.00 ➝ $10.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
$570K6.95N/AN/A$6.56 per share0.23
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
$250K6.72N/AN/A$2.34 per share0.27
Femasys Inc. stock logo
FEMY
Femasys
$1.07M27.47N/AN/A$0.85 per share1.56
Neovasc Inc. stock logo
NVCN
Neovasc
$3.81M21.60N/AN/A$5.77 per share5.20

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
-$12.03M-$4.99N/AN/AN/AN/A-106.28%-86.60%6/26/2024 (Estimated)
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
-$9.95M-$9.01N/AN/AN/A-168.38%-122.58%5/8/2024 (Estimated)
Femasys Inc. stock logo
FEMY
Femasys
-$14.25M-$0.92N/AN/AN/A-1,329.10%-105.47%-80.50%5/9/2024 (Estimated)
Neovasc Inc. stock logo
NVCN
Neovasc
-$41.20M-$15.08N/AN/A-1,082.92%-127.25%-80.31%N/A

Latest AEMD, BJDX, FEMY, and NVCN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
-$0.68-$1.78-$1.10-$1.78N/AN/A
3/28/2024Q4 2023
Femasys Inc. stock logo
FEMY
Femasys
-$0.19-$0.19N/A-$0.19$0.30 million$0.21 million
2/14/2024Q3 2024
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
-$1.23-$1.37-$0.14-$1.37N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
N/AN/AN/AN/AN/A
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
N/AN/AN/AN/AN/A
Femasys Inc. stock logo
FEMY
Femasys
N/AN/AN/AN/AN/A
Neovasc Inc. stock logo
NVCN
Neovasc
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
N/A
3.93
3.93
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
N/A
1.82
1.82
Femasys Inc. stock logo
FEMY
Femasys
0.24
7.59
7.37
Neovasc Inc. stock logo
NVCN
Neovasc
0.80
2.96
2.85

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
1.99%
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
18.47%
Femasys Inc. stock logo
FEMY
Femasys
65.27%
Neovasc Inc. stock logo
NVCN
Neovasc
1.64%

Insider Ownership

CompanyInsider Ownership
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
4.00%
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
47.00%
Femasys Inc. stock logo
FEMY
Femasys
16.39%
Neovasc Inc. stock logo
NVCN
Neovasc
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aethlon Medical, Inc. stock logo
AEMD
Aethlon Medical
152.62 million2.52 millionNo Data
Bluejay Diagnostics, Inc. stock logo
BJDX
Bluejay Diagnostics
102.69 million1.43 millionNot Optionable
Femasys Inc. stock logo
FEMY
Femasys
3222.10 million18.48 millionNot Optionable
Neovasc Inc. stock logo
NVCN
Neovasc
492.74 millionN/ANot Optionable

AEMD, BJDX, FEMY, and NVCN Headlines

SourceHeadline
Top Small-Cap Stocks for May 2023 - InvestopediaTop Small-Cap Stocks for May 2023 - Investopedia
news.google.com - May 13 at 9:38 AM
FDA accepts application for Roches Vabysmo for the - GlobeNewswireFDA accepts application for Roche's Vabysmo for the - GlobeNewswire
news.google.com - May 9 at 2:18 AM
New treatment option opens avenues in geographic atrophy - HealioNew treatment option opens avenues in geographic atrophy - Healio
news.google.com - May 8 at 9:18 PM
Pachychoroid neovasculopathy has clinical properties that differ ... - Nature.comPachychoroid neovasculopathy has clinical properties that differ ... - Nature.com
news.google.com - May 8 at 9:18 PM
The NOD audit provides data and insights for the management for ... - Modern RetinaThe NOD audit provides data and insights for the management for ... - Modern Retina
news.google.com - May 8 at 9:18 PM
Shockwave Medical Reports First Quarter 2023 Financial Results - GlobeNewswireShockwave Medical Reports First Quarter 2023 Financial Results - GlobeNewswire
news.google.com - May 8 at 4:17 PM
Heart valve repair and replacement devices market size to grow by ... - BenzingaHeart valve repair and replacement devices market size to grow by ... - Benzinga
news.google.com - May 5 at 9:03 PM
ASCRS: Prediction of imminent conversion to neovascular AMD ... - Optometry TimesASCRS: Prediction of imminent conversion to neovascular AMD ... - Optometry Times
news.google.com - May 5 at 4:02 PM
Faricimab in Treatment-Resistant nARMD | OPTH - Dove Medical PressFaricimab in Treatment-Resistant nARMD | OPTH - Dove Medical Press
news.google.com - May 5 at 12:24 AM
Restoring vision through retinal ganglion cell repopulation - Ophthalmology Times EuropeRestoring vision through retinal ganglion cell repopulation - Ophthalmology Times Europe
news.google.com - May 5 at 12:24 AM
STAR Trial: Surgery Not Superior to Pneumatic Displacement for ... - MD MagazineSTAR Trial: Surgery Not Superior to Pneumatic Displacement for ... - MD Magazine
news.google.com - May 4 at 7:24 PM
The NOD audit: Insights into the current state of management for ... - Nature.comThe NOD audit: Insights into the current state of management for ... - Nature.com
news.google.com - May 4 at 8:40 AM
On the horizon: Treatments for both forms of AMD - Ophthalmology Times EuropeOn the horizon: Treatments for both forms of AMD - Ophthalmology Times Europe
news.google.com - May 3 at 10:56 AM
Biosimilar Ranibizumab Displays Comparable Safety, Efficacy to ... - The Center for BiosimilarsBiosimilar Ranibizumab Displays Comparable Safety, Efficacy to ... - The Center for Biosimilars
news.google.com - April 28 at 3:22 PM
Real World Evidence Supporting GA Therapy Management Strategies - AJMC.com Managed Markets NetworkReal World Evidence Supporting GA Therapy Management Strategies - AJMC.com Managed Markets Network
news.google.com - April 28 at 10:22 AM
Low-vision services improve vision, quality of life in patients with ... - HealioLow-vision services improve vision, quality of life in patients with ... - Healio
news.google.com - April 28 at 10:22 AM
New Vabysmo data suggest greater retinal drying versus aflibercept ... - GlobeNewswireNew Vabysmo data suggest greater retinal drying versus aflibercept ... - GlobeNewswire
news.google.com - April 25 at 6:55 PM
New treatment tackles both forms of AMD - Ophthalmology TimesNew treatment tackles both forms of AMD - Ophthalmology Times
news.google.com - April 25 at 6:55 PM
Price Variation in Economic Evaluations of Infliximab Could ... - The Center for BiosimilarsPrice Variation in Economic Evaluations of Infliximab Could ... - The Center for Biosimilars
news.google.com - April 25 at 1:32 AM
1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - Yahoo Finance1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - Yahoo Finance
news.google.com - April 25 at 1:32 AM
Accel Research expands reach with acquisition of two Florida trial ... - FierceBiotechAccel Research expands reach with acquisition of two Florida trial ... - FierceBiotech
news.google.com - April 24 at 3:16 PM
Report: Boston Scientific considering massive deal to acquire ... - Cardiovascular BusinessReport: Boston Scientific considering massive deal to acquire ... - Cardiovascular Business
news.google.com - April 24 at 3:16 PM
Boston Sci Rumored to Be Interested in Acquiring Shockwave - Medical Device and Diagnostics IndustryBoston Sci Rumored to Be Interested in Acquiring Shockwave - Medical Device and Diagnostics Industry
news.google.com - April 21 at 4:24 PM
The Future of the Structural Heart Disease Intervention Devices ... - Digital JournalThe Future of the Structural Heart Disease Intervention Devices ... - Digital Journal
news.google.com - April 21 at 10:58 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aethlon Medical logo

Aethlon Medical

NASDAQ:AEMD
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.
Bluejay Diagnostics logo

Bluejay Diagnostics

NASDAQ:BJDX
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Femasys logo

Femasys

NASDAQ:FEMY
Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. In addition, the company provides non-surgical product technologies. It offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Neovasc logo

Neovasc

NASDAQ:NVCN
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.